MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-12-2025
Citius Pharmaceuticals Long Term Debt Current 2011-2025 | CTXR
Annual Long Term Debt Current Citius Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 242 K | 218 K | 197 K | 177 K | 159 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 242 K | 159 K | 199 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 25.27 | -2.43 % | $ 1.22 B | USA |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
481 K | $ 3.26 | -3.12 % | $ 252 M | USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Kamada Ltd.
KMDA
|
1.63 M | $ 7.03 | 0.14 % | $ 260 M |  Israel |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 220.27 | 4.81 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.3 | -3.51 % | $ 7.94 B |  Australia |
 |
AstraZeneca PLC
AZN
|
339 M | $ 89.78 | -0.57 % | $ 96.9 B | Britain |
 |
Anika Therapeutics
ANIK
|
1.6 M | $ 9.57 | 0.84 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | USA |
 |
Benitec Biopharma
BNTC
|
354 K | $ 12.05 | -7.06 % | $ 496 M | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.34 | 2.59 % | $ 14.7 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
23 K | - | -19.68 % | $ 18.4 M | Canada |
 |
Aptorum Group Limited
APM
|
433 K | $ 1.29 | -3.01 % | $ 7.03 M |  China |
 |
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 14.01 | -8.49 % | $ 922 M | USA |
 |
ChromaDex Corporation
CDXC
|
982 K | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
9.45 M | $ 566.18 | -2.56 % | $ 42.9 B | USA |
 |
Cerus Corporation
CERS
|
2.28 M | $ 2.16 | 0.47 % | $ 399 M | USA |
 |
Caladrius Biosciences
CLBS
|
137 K | - | -16.75 % | $ 25.8 M | USA |
 |
Biogen
BIIB
|
86.4 M | $ 174.42 | 1.11 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
74.5 K | $ 1.42 | -5.96 % | $ 2.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.45 M | $ 27.36 | -2.09 % | $ 1.76 M | USA |
 |
Cortexyme
CRTX
|
64 K | - | -1.05 % | $ 67.1 M | USA |
 |
Cellectar Biosciences
CLRB
|
59 K | $ 3.63 | -3.97 % | $ 44.4 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 11.54 | 0.87 % | $ 746 M | USA |